Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy water (2H2O) labeling method. This study is exploring the time profile of appearance and disappearance of pulse deuterium-labeled cargo proteins in CSF of subjects with AD and/or PSP, which is different from healthy controls, due to deficits in fast axonal transport.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement

NCT07313098

Neurologic Disorder Central Nervous System Diseases

NOT_YET_RECRUITING

MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics

NCT04099823

Hydrocephalus Alzheimer Disease

RECRUITING NA

A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease

NCT01436188

Healthy Alzheimer Disease

COMPLETED EARLY_PHASE1

A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)

NCT00757939

Alzheimer's Disease

COMPLETED PHASE1

BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

NCT00887601

Dementia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective:

To compare the time profile of appearance and disappearance in CSF of pulse deuterium-labeled chromogranin B, sAPPα and β-Trace in AD and PSP subjects compared to healthy controls.

Secondary Objectives:

* To measure body water enrichment of deuterium in saliva and plasma (2H-enrichment (%))
* To explore the effect of age on the kinetics of deuterium labeling of CSF biomarkers
* To assess intra and inter subject variability of deuterium-labeling of chromogranin B, sAPPα and β-Trace

Subjects will undergo screening evaluations to determine eligibility prior to heavy water (2H20) administration. Eligible subjects will be admitted to the clinical facility on Day -1. On Day 1, subjects will ingest small doses of 2H20 during their inpatient stay. They will also drink 2H20 for 7 more days. Subjects will undergo two lumbar punctures (LPs) for CSF samples. Subjects will return to the study site approximately 7 days after the last LP (or early termination) for a follow-up assessment and discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Progressive Supranuclear Palsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elderly Healthy Control (EHV)

No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.

No interventions assigned to this group

Progressive Supranuclear Palsy (PSP)

A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.

No interventions assigned to this group

Alzheimer's Disease (AD)

A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects

* Body Mass Index of 18-32.
* Subjects can have common non-neurological age-related disorders (hypertension, diabetes) and on stable medication for the last 3 months.
* Screening score of \< 4 on the Modified Hachinski Ischemia Scale.
* Women not of childbearing potential and men.
* Women with negative pregnancy test prior to starting heavy water and not breastfeeding.

AD

* Diagnosis of probable AD.
* Mild to moderate disease severity according to mini-mental state examination score (MMSE) of 16-26.
* Documented cognitive decline began 6 months prior to screening.
* On stable doses of approved AD medications for 2 months prior to screening.
* Non-medicated AD subjects are free of AD medications for 2 months prior to screening.
* Mild to moderate white matter disease and up to 2 lacunar infarcts acceptable as determined by brain MRI at screening.
* Investigator determines subjects to be medically stable and physically able to complete the study.
* Minimum of 6 years of education and able to read, write and communicate effectively.
* Adequate hearing, vision, and language skills.
* Subjects and their caregivers must agree to the dosage regimens and procedures, report for scheduled visits, and communicate with study personnel.

PSP

* Diagnosis of probable PSP.
* Brain MRI at screening excluding potential causes of parkinsonism, especially cerebrovascular and space occupying lesions.
* Mild-to-moderate stage of disease severity by a Golbe Staging System score of 1-3.
* Subjects and their caregivers must agree to the dosage regimens and procedures, report for scheduled visits, and communicate with study personnel.
* Currently on stable doses of PSP medications for 2 months prior to screening.
* Investigator determines subjects to be medically stable and able to complete the study.
* Minimum of 6 years of education and able to read, write and communicate effectively.
* Adequate hearing, vision, and language skills.

EHV

* No clinically significant deviation from healthy for their age group.
* No subjective or objective memory loss.
* MMSE score of 28 to 30.

Exclusion Criteria

* Diseased subjects with a medical condition (not AD or PSP) that could contribute to the subjects dementia or Parkinsonism.
* History of pallidotomy, thalamotomy, active DBS or fetal tissue transplant.
* Any significant acute or chronic illness.
* Major surgery within 4 weeks of Day 1.
* Blood/plasma donation to a blood bank or a clinical study (except a screening visit) within 4 weeks of Day 1.
* Blood transfusion within 4 weeks of Day 1.
* Inability to be venipunctured.
* Inability to be lumbar punctured or contraindications to lumbar puncture or epidurals.
* \> 10 cigarettes/day.
* Recent drug or alcohol abuse or positive urine screen for drugs of abuse.
* Subjects deemed inappropriate to undergo a MRI.
* Any medical, psychiatric or social reason as determined by the investigator.
* AD subjects with a history of CSF or amyloid imaging studies not consistent with Alzheimer's pathology.
* Healthy subjects with a history of CSF or amyloid imaging studies consistent with Alzheimer's pathology.
* Allergies to local anesthetics.
* Any significant drug allergy.

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes